Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Inclusion Criteria

• •Clinical and laboratory diagnosis of CBF-AML,including RUNX1-RUNX1T1 and CBF-MYH11 fusion gene rearrangement by PCR/FISH
• •In status of complete remission after one to two courses of induction therapy
• •Total bilirubinic acid ≤ 35μmol/L, AST/ALT\<2 times abnormal level, serum creatinine \< 1.5mg/ml
• •Cardiac function: EF ≥ 50%
• •Hydroxyurea can be used for patient with white blood cell count ≥ 50\*109/L
• •ECOG (Eastern Cooperative Oncology Group) score: ≤ 2